References

What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia?

10.1002/wps.20516 · 2018 · External reference

Re-evaluating the prognosis of schizophrenia: tackling the issue of inadequate treatment

10.1080/14737175.2024.2365943 · 2024 · External reference

Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review

10.1177/2045125312474019 · 2013 · External reference

Medicinal chemistry based approaches and nanotechnology-based systems to improve CNS drug targeting and delivery

10.1002/med.21252 · 2013 · External reference

Advancements in Using Polymeric Nanoparticles for Blood–Brain Barrier Penetration in Neurological Disorders

10.1021/acsabm.4c01956 · 2025 · External reference

Effectiveness of second-generation antipsychotics: a naturalistic, randomized comparison of olanzapine, quetiapine, risperidone, and ziprasidone

10.1186/1471-244x-10-26 · 2010 · External reference

Preparation, characterization and evaluation of quetiapine fumarate solid lipid nanoparticles to improve the oral bioavailability

2013 · External reference

Cardiac adverse events associated with quetiapine: disproportionality analysis of FDA adverse event reporting system

10.1111/cns.14215 · 2023 · External reference

Quetiapine fumarate overdose: clinical and pharmacokinetic lessons from extreme conditions

10.1067/mcp.2000.107507 · 2000 · External reference

Intranasal drug delivery technology in the treatment of central nervous system diseases: challenges, advances, and future research directions

10.3390/pharmaceutics17060775 · 2025 · External reference

The nasal mucociliary clearance: relevance to nasal drug delivery

10.1023/a:1015830907632 · 1991 · External reference

Drug delivery and targeting to the brain through nasal route: mechanisms, applications and challenges

10.2174/1567201816666191029122740 · 2019 · External reference

The ascension of nanosponges as a drug delivery carrier: preparation, characterization, and applications

10.1007/s10856-022-06652-9 · 2022 · External reference

Nanosponges for drug delivery and cancer therapy: Recent advances

10.3390/nano12142440 · 2022 · External reference

In situ gels for nasal delivery: Formulation, characterization and applications

10.1002/mame.202400356 · 2025 · External reference

A Nanoemulgel for Nose-to-Brain delivery of Quetiapine–QbD-Enabled formulation development & in-vitro characterization

10.1016/j.ijpharm.2023.123566 · 2023 · External reference

Plackett-Burman design for screening of critical variables and their effects on the optical transparency and swelling of gatifloxacin-Pluronic-loaded contact lens

10.1016/j.ijpharm.2019.06.008 · 2019 · External reference

QBD approach for the development of hesperetin loaded colloidal nanosponges for sustained delivery: In-vitro, ex-vivo, and in-vivo assessment

10.1016/j.onano.2022.100045 · 2022 · External reference

An overview of mucoadhesive thermoreversible nasal gel

2021 · External reference

Formulation and in vitro evaluation of topical nanosponge-based gel containing butenafine for the treatment of fungal skin infection

10.1016/j.jsps.2021.04.010 · 2021 · External reference

Formulation and development of posaconazole loaded controlled release nanosponge topical gel for the treatment of fungal infection

10.1007/s12247-024-09912-z · 2025 · External reference

Fabrication, characterization, and docking studies of furosemide-loaded nanosponges using the emulsion solvent diffusion method

10.1080/17435889.2025.2501518 · 2025 · External reference

Design and optimization of curcumin loaded nano lipid carrier system using Box-Behnken design

10.1016/j.biopha.2021.111919 · 2021 · External reference

Multiple response optimisation of processing and formulation parameters of pH sensitive sustained release pellets of capecitabine for targeting colon

10.1080/02652048.2018.1465138 · 2018 · External reference

Formulation and optimization of transferrin-modified genistein nanocrystals: In vitro anti-cancer assessment and pharmacokinetic evaluation

10.1016/j.ijpharm.2024.124863 · 2024 · External reference

Formulation and evaluation of clindamycin HCL in situ gel for vaginal application

10.4103/2230-973x.147233 · 2015 · External reference

Formulation and evaluation of gliclazide nanosponges

10.22159/ijap.2019v11i6.35006 · 2019 · External reference

Tailored doxycycline hyclate loaded in situ gel for the treatment of periodontitis: Optimization, in vitro characterization, and antimicrobial studies

10.1208/s12249-021-01950-x · 2021 · External reference

A 3 2 full factorial design for development and characterization of a nanosponge-based intravaginal in situ gelling system for vulvovaginal candidiasis

10.1039/c5ra26218f · 2016 · External reference

Development and evaluation of hydrogel-based sulfasalazine-loaded nanosponges for enhanced topical psoriasis therapy

10.3390/ph18030391 · 2025 · External reference

Development of a Gellan–Carbopol in Situ Gel System for Intranasal Delivery of Artemether-Loaded SLNs: Optimization and Kinetic Evaluation

10.1007/s12247-025-10263-6 · 2026 · External reference

Formulation and evaluation of thermoreversible, mucoadhesive in situ intranasal gel of rizatriptan benzoate

10.1007/s10971-014-3422-5 · 2014 · External reference

Intranasal delivery of doxepin: enhancing brain targeting efficiency utilizing nanostructured lipid carriers for a biopharmaceutics drug disposition classification system class-I drug

10.1080/10837450.2024.2376102 · 2024 · External reference

Clozapine-laden carbon dots delivered to the brain via an intranasal pathway: Synthesis, characterization, ex vivo, and in vivo studies

10.1016/j.colsurfb.2024.113862 · 2024 · External reference

Unresolved reference

External reference

Intranasal nano-delivery systems: emerging strategies for central nervous system disease therapeutics

2026 · External reference

Development and evaluation of scaffold-based nanosponge formulation for controlled drug delivery of naproxen and ibuprofen

10.4314/tjpr.v17i8.2 · 2018 · External reference

Development and evaluation of polymeric nanosponge hydrogel for terbinafine hydrochloride: statistical optimization, in vitro and in vivo studies

2020 · External reference

Microsponge based gel as a simple and valuable strategy for formulating and releasing Tazarotene in a controlled manner

10.1038/s41598-022-15655-z · 2022 · External reference

Optimisation of a greener-approach for the synthesis of cyclodextrin-based nanosponges for the solubility enhancement of domperidone, a BCS class II drug

10.3390/ph16040567 · 2023 · External reference

Ethyl-cellulose nanosponges for topical delivery of simvastatin with preferential skin retention for wound healing in a full-thickness wound rat model

10.1208/s12249-025-03114-7 · 2025 · External reference

Development and Invitro Characterization of Nanosponge Formulation of Lovastatin for Oral Delivery Using a Central Composite Design

2025 · External reference

Screening of adapalene microsponges fabrication parameters with insight on the in vitro biological effectiveness

10.2147/dddt.s383051 · 2022 · External reference

Revolutionizing Drug Delivery: The Impact of Microsponges in Pharmaceutical Research

10.2174/0122103031308362240806113226 · 2025 · External reference

Preparation of posaconazole nanosponges for improved topical delivery system

10.25258/ijddt.12.1.2 · 2022 · External reference

The effect of formulation and process variables on prepared etoricoxib Nanosponges

10.51847/q0qrkuv2kq · 2021 · External reference

Development of abemaciclib-encapsulated nanosponges for breast cancer: optimization, drug release kinetics, and in vitro efficacy

10.69857/joapr.v13i4.1234 · 2025 · External reference

Receptor occupancy and brain free fraction

10.1124/dmd.108.022814 · 2009 · External reference

A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy

10.1001/archpsyc.57.6.553 · 2000 · External reference